GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Frontage Holdings Corp (HKSE:01521) » Definitions » 3-Year EPS without NRI Growth Rate

Frontage Holdings (HKSE:01521) 3-Year EPS without NRI Growth Rate : 6.70% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Frontage Holdings 3-Year EPS without NRI Growth Rate?

Frontage Holdings's EPS without NRI for the six months ended in Dec. 2023 was HK$0.05.

During the past 12 months, Frontage Holdings's average EPS without NRI Growth Rate was -32.60% per year. During the past 3 years, the average EPS without NRI Growth Rate was 6.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 5.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 8 years, the highest 3-Year average EPS without NRI Growth Rate of Frontage Holdings was 44.20% per year. The lowest was 6.70% per year. And the median was 14.50% per year.


Competitive Comparison of Frontage Holdings's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Frontage Holdings's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Frontage Holdings's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Frontage Holdings's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Frontage Holdings's 3-Year EPS without NRI Growth Rate falls into.



Frontage Holdings 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Frontage Holdings  (HKSE:01521) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Frontage Holdings 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Frontage Holdings's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Frontage Holdings (HKSE:01521) Business Description

Industry
Traded in Other Exchanges
Address
700 Pennsylvania Drive, Exton, PA, USA, 19341
Frontage Holdings Corp is a contract research organization providing integrated, scientifically driven research, analytical and development services. Geographically the group operates in both PRC and North America. The services provided in the North American segment, include Bioanalytical, CMC, DMPK and Safety and Toxicology services in the USA and Canada. The service offered in PRC includes Bioanalytical, Bioequivalence and CMC services in the PRC. Further, it also provides bioanalytical services, which are offered throughout the drug discovery and development process both in the United States and China.
Executives
Hang Zhou Tai Ge Yi Yao Ke Ji Gu Fen You Xian Gong Si 2101 Beneficial owner
Li Song 2101 Beneficial owner
Kabouter Management Llc 2102 Investment manager
Hangzhou Tigermed Consulting Co., Ltd.
Hongkong Tigermed Co., Limited

Frontage Holdings (HKSE:01521) Headlines

No Headlines